FluMist is a nasally-administered influenza vaccine that is indicated for active immunization to prevent influenza disease in individuals 2 to 49 years of age.

The Food and Drug Administration (FDA) has approved Miplyffa ™ (arimoclomol) for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) ...

Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

Baloxavir marboxil significantly reduced the likelihood of influenza transmission from the infected patient to the household contacts. Treatment with baloxavir marboxil significantly reduced the risk ...